Table 1.
Baseline Characteristics
| Characteristics | Cohort 1 n = 31 |
Cohort 2 n = 93 |
Cohort 3 n = 13 |
Total N = 137 |
|---|---|---|---|---|
| Median age (range), years | 68 (42–85) | 65 (44–85) | 65 (52–74) | 66 (42–85) |
| Sex, n (%) | ||||
| Male | 14 (45) | 59 (63) | 6 (46) | 79 (58) |
| Female | 17 (55) | 34 (37) | 7 (54) | 58 (42) |
| Histology, n (%) | 11 (36) | 26 (28) | 1 (8) | 38 (28) |
| Non-squamous | ||||
| Squamous | 20 (65) | 67 (72) | 12 (92) | 99 (72) |
| Tobacco use, n (%) | ||||
| Never | 3 (10) | 16 (17) | 1 (8) | 20 (15) |
| Current | 3 (10) | 13 (14) | 2 (15) | 18 (13) |
| Previous | 25 (81) | 64 (69) | 10 (77) | 99 (72) |
| ECOG PS, n (%) | ||||
| 0 | 11 (36) | 24 (26) | 6 (46) | 41 (30) |
| 1 | 20 (65) | 68 (74) | 7 (54) | 95 (70) |
| Missing | 0 (0) | 1 (1) | 0 (0) | 1 (1) |
| EGFR mutation status, n (%) | 13 | 51 | 7 | 71 |
| Positive | 0 (0) | 5 (10) | 3 (43) | 8 (11) |
| Negative | 13 (100) | 44 (86) | 4 (57) | 61 (86) |
| T790M | 0 (0) | 2 (4) | 0 (0) | 2 (3) |
| ALK mutation positive, n (%) | 20 | 65 | 10 | 95 |
| Positive | 0 (0) | 1 (2) | 0 (0) | 1 (1) |
| Negative | 20 (100) | 64 (99) | 10 (100) | 94 (99) |
| PD-L1 TC/IC status, n (%) | ||||
| TC2 or IC2/3 | 28 (90) | 78 (84) | 12 (92) | 118 (86) |
| TC3 or IC3 | 7 (23) | 38 (41) | 8 (62) | 53 (39) |
ALK, anaplastic lymphoma kinase; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; IC, tumor-infiltrating immune cell (IC2/3; 5% to <10%/≥10% PD-L1 staining); PD-L1, programmed death ligand-1; TC, tumor cell (TC2/3; 5% to <50%/≥50% PD-L1 staining).